{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:26:06Z","timestamp":1794493566547,"version":"4.9.1"},"reference-count":80,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and\/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label. In this review, we discuss some controversial diagnostic and therapeutic aspects of PCOS, such as the role of insulin resistance, inflammation, and hyperandrogenism. We also evaluated the advantages and disadvantages of contraceptive therapy and antiandrogens.<\/jats:p>","DOI":"10.3390\/ijms23084110","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:11:14Z","timestamp":1649419874000},"page":"4110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":305,"title":["Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-5155","authenticated-orcid":false,"given":"Decio","family":"Armanini","sequence":"first","affiliation":[{"name":"Department of Medicine-Endocrinology, University of Padua, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Boscaro","sequence":"additional","affiliation":[{"name":"Department of Medicine-Endocrinology, University of Padua, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4238-3153","authenticated-orcid":false,"given":"Luciana","family":"Bordin","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine-Biological Chemistry, University of Padua, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1526-6832","authenticated-orcid":false,"given":"Chiara","family":"Sabbadin","sequence":"additional","affiliation":[{"name":"Department of Medicine-Endocrinology, University of Padua, 35100 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS). Hum. Reprod., 19, 41\u201347.","DOI":"10.1093\/humrep\/deh098"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cen.13795","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"89","author":"Teede","year":"2018","journal-title":"Clin. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coemr.2020.02.013","article-title":"Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective","volume":"12","author":"Dumesic","year":"2020","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications","volume":"33","author":"Dunaif","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2337\/diab.41.10.1257","article-title":"Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome","volume":"41","author":"Dunaif","year":"1992","journal-title":"Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2006.05.006","article-title":"Molecular mechanisms of insulin resistance in polycystic ovary syndrome","volume":"12","author":"Papavassiliou","year":"2006","journal-title":"Trends Mol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mehy.2012.04.016","article-title":"Dysbiosis of Gut Microbiota (DOGMA)\u2014A novel theory for the development of Polycystic Ovarian Syndrome","volume":"79","author":"Tremellen","year":"2012","journal-title":"Med. Hypotheses"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5468\/ogs.21185","article-title":"A narrative review of the role of gastrointestinal dysbiosis in the pathogenesis of polycystic ovary syndrome","volume":"65","author":"Parker","year":"2022","journal-title":"Obstet. Gynecol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1210\/jc.2007-1834","article-title":"Impact of obesity on the risk for polycystic ovary syndrome","volume":"93","author":"Yildiz","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/S1462399408000598","article-title":"Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications","volume":"10","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A.M., Smolarczyk, R., and Meczekalski, B. (2021). Chronic low grade inflammation in pathogenesis of PCOS. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073789"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fendo.2019.00575","article-title":"Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy","volume":"10","author":"Sabbadin","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.steroids.2012.02.010","article-title":"Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone","volume":"77","author":"Armanini","year":"2012","journal-title":"Steroids"},{"key":"ref_15","first-page":"S157","article-title":"Binding of agonists and antagonists to mineralocorticoid receptors in human peripheral mononuclear leucocytes","volume":"3","author":"Armanini","year":"1985","journal-title":"J. Hypertens. Suppl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1210\/jc.2003-031545","article-title":"Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes","volume":"89","author":"Zaghetto","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"139239","DOI":"10.1155\/2013\/139239","article-title":"Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines","volume":"2013","author":"Makki","year":"2013","journal-title":"ISRN Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2119\/2007-00119.Tilg","article-title":"Inflammatory mechanisms in the regulation of insulin resistance","volume":"14","author":"Tilg","year":"2008","journal-title":"Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/cen.13808","article-title":"Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS","volume":"89","author":"Shorakae","year":"2018","journal-title":"Clin. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Aboeldalyl, S., James, C., Seyam, E., Ibrahim, E.M., Shawki, H.E., and Amer, S. (2021). The role of chronic inflammation in polycystic ovarian syndrome-A systematic review and meta-analysis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052734"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1210\/jc.2004-0934","article-title":"Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome","volume":"89","author":"Yildiz","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0889-8529(05)70070-0","article-title":"Ovarian and adrenal function in polycystic ovary syndrome","volume":"28","author":"Rosenfield","year":"1999","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1210\/jc.2003-030240","article-title":"Altered cortisol metabolism in polycystic ovary syndrome: Insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates","volume":"88","author":"Tsilchorozidou","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E628","DOI":"10.1210\/jc.2012-3908","article-title":"Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome","volume":"98","author":"Moghetti","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1080\/14656566.2016.1215430","article-title":"Spironolactone in the treatment of polycystic ovary syndrome","volume":"17","author":"Armanini","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/joe.1.07070","article-title":"Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women","volume":"192","author":"Corbould","year":"2007","journal-title":"J. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Allemand, M.C., Irving, B.A., Asmann, Y.W., Klaus, K.A., Tatpati, L., Coddington, C.C., and Nair, K.S. (2009). Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes\u2014A potential model for PCOS-related insulin resistance. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004274"},{"key":"ref_29","first-page":"2633494120913032","article-title":"Controversies in the diagnosis of polycystic ovary syndrome","volume":"14","author":"Rao","year":"2020","journal-title":"Ther. Adv. Reprod. Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: Consequences, challenges, and guiding treatment","volume":"106","author":"Hoeger","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Androgen excess society. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tem.2014.12.003","article-title":"Metabolic risk in PCOS: Phenotype and adiposity impact","volume":"26","author":"Moran","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12958-016-0203-8","article-title":"Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: A meta-analysis","volume":"14","author":"Yang","year":"2016","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dapas, M., Lin, F.T.J., Nadkarni, G.N., Sisk, R., Legro, R.S., Urbanek, M., Hayes, M.G., and Dunaif, A. (2020). Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003132"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jc.2018-00241","article-title":"Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline","volume":"103","author":"Martin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1210\/jc.2016-3285","article-title":"11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome","volume":"102","author":"Kempegowda","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Parker, J., O\u2019Brien, C., Hawrelak, J., and Gersh, F.L. (2022). Polycystic ovary syndrome: An evolutionary adaptation to lifestyle and the environment. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19031336"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/humrep\/dew243","article-title":"Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies","volume":"31","author":"Cassar","year":"2016","journal-title":"Hum. Reprod."},{"key":"ref_40","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2337\/diacare.23.1.57","article-title":"Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity","volume":"23","author":"Bonora","year":"2000","journal-title":"Diabetes Care"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1507\/endocrj.EJ19-0445","article-title":"Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor","volume":"67","author":"So","year":"2020","journal-title":"Endocr. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/humrep\/dex308","article-title":"Insulin resistance in a large cohort of women with polycystic ovary syndrome: A comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes","volume":"32","author":"Tosi","year":"2017","journal-title":"Hum. Reprod."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40618-020-01351-0","article-title":"Insulin resistance and PCOS: Chicken or egg?","volume":"44","author":"Moghetti","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.steroids.2014.06.005","article-title":"Lipid profile in nonobese pregnant women with polycystic ovary syndrome: A prospective controlled clinical study","volume":"88","author":"Palomba","year":"2014","journal-title":"Steroids"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","first-page":"53","article-title":"Metabolic health during a randomized controlled lifestyle intervention in women with PCOS","volume":"186","author":"Jiskoot","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., and Scaroni, C. (2020). Pharmacological approaches to controlling cardiometabolic risk in women with PCOS. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249554"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review","volume":"30","author":"Palomba","year":"2009","journal-title":"Endocr. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"C873","DOI":"10.1152\/ajpcell.00604.2020","article-title":"The intersection of metformin and inflammation","volume":"320","author":"Bharath","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1210\/jc.2003-030562","article-title":"Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome","volume":"88","author":"Elsenbruch","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/09513590.2010.500818","article-title":"Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS","volume":"26","author":"Genazzani","year":"2010","journal-title":"Gynecol. Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C.O., Greene, N.D., Bizzarri, M., Lagan\u00e0, A.S., Chan, S.Y., Bevilacqua, A., and Pkhaladze, L. (2021). Inositols: From established knowledge to novel approaches. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910575"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1530\/EJE-11-0840","article-title":"Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome","volume":"166","author":"Sabbadin","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tem.2020.02.002","article-title":"Inositols in polycystic ovary syndrome: An overview on the advances","volume":"31","author":"Facchinetti","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17512433.2021.1933433","article-title":"Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome","volume":"14","author":"Siamashvili","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3892\/etm.2016.3081","article-title":"Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study","volume":"11","author":"Jensterle","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Marrioneaux","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., and Tentolouris, N. (2019). SGLT2 Inhibitors: A review of their antidiabetic and cardioprotective effects. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16162965"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4239\/wjd.v12.i7.932","article-title":"Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor","volume":"12","author":"Kruezi","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Montandon, S.A., and Jornayvaz, F.R. (2017). Effects of antidiabetic drugs on gut microbiota composition. Genes, 8.","DOI":"10.3390\/genes8100250"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1210\/jc.2016-2586","article-title":"Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women","volume":"101","author":"Dumesic","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.steroids.2013.04.009","article-title":"Cardiovascular disease risk in women with PCOS","volume":"78","author":"Dokras","year":"2013","journal-title":"Steroids"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.fertnstert.2008.09.034","article-title":"Endothelial function and insulin resistance in polycystic ovary syndrome: The effects of medical therapy","volume":"93","author":"Teede","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jth.12224","article-title":"Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of ethinyl-estradiol?","volume":"11","author":"Bird","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","article-title":"Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study","volume":"183","author":"Gronich","year":"2011","journal-title":"CMAJ"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1210\/jc.2006-0399","article-title":"Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome","volume":"91","author":"Cascella","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2007-1016296","article-title":"Adrenal involvement in polycystic ovary syndrome","volume":"15","author":"Gonzalez","year":"1997","journal-title":"Semin Reprod. Endocrinol."},{"key":"ref_70","first-page":"315","article-title":"Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism","volume":"10","author":"Bastianelli","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17425255.2016.1190832","article-title":"Metabolic impact of combined hormonal contraceptives containing estradiol","volume":"12","author":"Grandi","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"bqab259","DOI":"10.1210\/endocr\/bqab259","article-title":"Estrogen and progesterone therapy and meningiomas","volume":"163","author":"Hage","year":"2022","journal-title":"Endocrinology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0015-0282(16)59346-7","article-title":"The endocrine effects of spironolactone used as an antiandrogen","volume":"48","author":"Young","year":"1987","journal-title":"Fertil. Steril."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/14656566.2014.896901","article-title":"Aldosterone receptor blockers spironolactone and canrenone: Two multivalent drugs","volume":"15","author":"Armanini","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40618-016-0466-0","article-title":"Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI","volume":"39","author":"Sabbadin","year":"2016","journal-title":"J. Endocrinol. Invest."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fendo.2019.00484","article-title":"Licorice: From pseudohyperaldosteronism to therapeutic uses","volume":"10","author":"Sabbadin","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejogrb.2006.10.013","article-title":"Treatment of polycystic ovary syndrome with spironolactone plus licorice","volume":"131","author":"Armanini","year":"2007","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_78","first-page":"1115","article-title":"Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism","volume":"79","author":"Moghetti","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0015-0282(16)57785-1","article-title":"Flutamide in the treatment of hirsutism: Long-term clinical effects, endocrine changes, and androgen receptor behavior","volume":"64","author":"Moghetti","year":"1995","journal-title":"Fertil. Steril."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1665-2681(19)31595-9","article-title":"Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature","volume":"10","author":"Brahm","year":"2011","journal-title":"Ann. Hepatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:50:11Z","timestamp":1760136611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":80,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23084110"],"URL":"https:\/\/doi.org\/10.3390\/ijms23084110","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]}}}